In the Original Publication of the article, In Introduction part, 7th line, the value “5-100nM” has been published incorrectly. The correct value should read as “Plasma concentration of 50-100ng/ml”. In the Original Publication of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown in the following page.
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5) / Buti, S.; Donini, M.; Bersanelli, M.; Gattara, A.; Leonardi, F.; Passalacqua, R.. - In: DRUGS IN R&D. - ISSN 1174-5886. - 18:2(2018), pp. 163-163. [10.1007/s40268-018-0234-z]
Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study (Drugs in R&D, (2017), 17, 4, (585-596), 10.1007/s40268-017-0209-5)
Buti S.;Bersanelli M.;Leonardi F.;
2018-01-01
Abstract
In the Original Publication of the article, In Introduction part, 7th line, the value “5-100nM” has been published incorrectly. The correct value should read as “Plasma concentration of 50-100ng/ml”. In the Original Publication of the article, page 591, Table 2 has been published incorrectly. The corrected table is shown in the following page.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
